The significance of AAVs in gene therapy cannot be overstated; these viruses are notably non-pathogenic and possess a remarkable ability to transduce a range of cell types. Their unique properties make them a staple in delivering genetic material, making them valuable tools in genetic research and clinical applications. The primary goal of Stamataki’s study was to identify AAV variants that exhibit superior transduction capabilities, enhancing their effectiveness in therapeutic settings involving human vascular endothelial cells.

One of the critical challenges in gene therapy is achieving efficient and targeted delivery of therapeutic genes to the desired cells. Traditional methods often fall short due to limitations in the natural tropism of AAVs, which necessitates the exploration of modified or optimized viral capsid variants. The research team embarked on an extensive screening process, utilizing AAV capsid libraries to isolate specific variants with enhanced binding and transduction efficiency for vascular endothelial cells. This innovative approach represents a significant leap forward in the ongoing quest for optimizing viral vectors for gene therapy.

In order to achieve their research objectives, the authors implemented various methodologies including in vivo evaluations in non-human primates. This approach is crucial as it provides a more accurate reflection of how these modified AAV variants might behave in human subjects. The use of non-human primates also helps to bridge the gap between preclinical studies and eventual clinical applications, ensuring that the findings are not only effective in laboratory settings but also viable in more complex biological systems.

The results of the study are promising, indicating a successful identification of novel AAV variants that demonstrated significantly improved transduction capacities in human vascular endothelial cells. This enhancement is crucial for the potential treatment of vascular diseases, where targeted gene therapy could revolutionize how such conditions are approached. The ability to efficiently deliver therapeutic genes directly into endothelial cells could lead to more effective interventions, reducing the risk of off-target effects and increasing the precision of therapeutic outcomes.

Furthermore, the study delves into the mechanisms that underlie the improved transduction observed with these novel AAV variants. By analyzing the interaction between the modified AAV capsids and the endothelial cell receptors, the researchers elucidated how certain mutations in the capsid proteins facilitate enhanced cellular uptake and gene expression. These insights can inform future research directives aimed at crafting even more potent AAV variants for diverse applications in gene therapy.

An important aspect of the research is its implications for the broader field of cardiovascular medicine. Cardiovascular diseases pose significant health burdens globally, and the ability to directly modify the endothelial cells responsible for vascular function presents a new frontier in treatment options. Gene therapy utilizing optimized AAVs could pave the way for innovative strategies to combat a range of vascular disorders, including atherosclerosis and hypertension, thereby potentially saving countless lives.

In addition to cardiovascular applications, the findings also open doors for other therapeutic realms, further emphasizing the versatility of AAV vectors. The study’s implications could resonate in various fields, including regenerative medicine, where targeted gene delivery may enhance tissue repair processes. The prospects of utilizing modified AAVs extend to a myriad of diseases, suggesting a bright future for gene therapy as a whole.

The authors also addressed the potential challenges and ethical considerations of using non-human primates for their research. This aspect of the study highlights the necessity of adhering to ethical guidelines while pushing the boundaries of scientific discovery. The careful selection of non-human primates as models serves to ensure that the research is conducted responsibly while still adhering to the rigor and validity required for such groundbreaking work.

In summary, Stamataki and colleagues have contributed substantially to the landscape of genetic research through their identification of AAV variants with enhanced transduction properties. By pioneering techniques that incorporate AAV capsid libraries and validate findings in non-human primates, they have set a precedent for future investigations into gene therapy. The implications of their work extend far beyond endothelial cells and could revolutionize therapeutic strategies across various medical sectors.

As the field of gene therapy continues to evolve, studies like this are essential for addressing the complex challenges posed by disease treatment and prevention. The pursuit of optimized AAV variants serves as a testament to the innovative spirit of researchers dedicated to harnessing the power of viral vectors for the betterment of human health. With ongoing advancements and discoveries, the horizon of gene therapy appears increasingly optimistic, holding the potential to transform clinical practice and significantly improve patient outcomes.

The research conducted signifies a monumental shift in the gene therapy paradigm, emphasizing the importance of engineering viral vectors that not only deliver genes effectively but also do so with precision and efficiency. As we look forward to the future of gene therapy, the contributions of Stamataki et al. will undoubtedly resonate within the scientific community and inspire a new generation of innovative research aimed at treating some of the most challenging diseases.

In conclusion, the identification of AAV variants with better transduction capabilities marks a critical development in the ongoing search for more effective gene therapy modalities. As the scientific community builds upon these findings, we are reminded of the endless possibilities inherent in the intersection of virology, genetics, and medicine, and how such synergy can ultimately lead to transformative therapies that have far-reaching impacts on humanity.

Subject of Research: Enhanced transduction of human vascular endothelial cells using identified AAV variants.

Article Title: Correction: Identification of AAV variants with improved transduction of human vascular endothelial cells by screening AAV capsid libraries in non-human primates.

Article References: Stamataki, M., Lüschow, J., Schlumbohm, C. et al. Correction: Identification of AAV variants with improved transduction of human vascular endothelial cells by screening AAV capsid libraries in non-human primates. Gene Ther (2025). https://doi.org/10.1038/s41434-025-00565-2

Image Credits: AI Generated

DOI: 10.1038/s41434-025-00565-2

Keywords: AAV variants, gene therapy, vascular endothelial cells, transduction efficiency, capsid libraries.

Atherosclerosis, the pathological underpinning of many heart attacks and strokes, involves complex cellular interactions and gene regulatory networks modulated by miRNAs. Therapeutic approaches now leverage the nuanced roles miRNAs play in endothelial cells, macrophages, and vascular smooth muscle cells to stabilize plaques, reduce inflammation, and prevent vascular occlusion. These interventions transcend traditional pharmacology by deploying synthetic delivery systems, including nanoparticles and engineered exosomes, designed to modulate miRNA expression with high precision.

Salvianolic acid, a biologically active component derived from Salvia miltiorrhiza, exemplifies such targeted chemical therapies. It operates by upregulating let-7g expression in macrophages, leading to decreased foam cell formation—a critical step in plaque development—while simultaneously downregulating miR-338-3p in endothelial cells to protect against apoptosis. Moreover, this compound induces the transfer of miR-204-5p via endothelial cell-derived extracellular vesicles to smooth muscle cells, activating autophagy pathways that suppress cell death and foster plaque stability. Such multi-cellular regulatory effects underscore the therapeutic finesse miRNA modulation can achieve.

Parallel to chemical agents, nanotechnology innovations have revolutionized miRNA delivery and targeting. Surface modification of extracellular vesicles or nanostructures with ligands like hyaluronic acid enables selective binding to CD44 receptors on pro-inflammatory macrophages in atheromas, facilitating the enhanced delivery of miR-34c-5p and consequent reprogramming of macrophages from the pro-inflammatory M1 to the reparative M2 phenotype. This repolarization reduces local inflammation and supports vascular healing. Likewise, ultrasound-targeted microbubble disruption facilitates the selective delivery of miR-145a-5p to vascular smooth muscle cells, promoting a contractile phenotype essential for vascular integrity.

Another remarkable vector involves spherical nucleic acid nanostructures carrying miR-146a, which can autonomously enter macrophages and endothelial cells to regulate NF-κB signaling, a pivotal inflammatory cascade in atherosclerosis progression. Intriguingly, nanoparticles with the pH low insertion peptide (pHLIP) have been engineered to transport antisense oligonucleotides against miR-33 selectively into macrophages, thereby enhancing the expression of fibrogenic genes essential for plaque stabilization in advanced disease stages.

When atherosclerosis culminates in myocardial infarction, therapeutic miRNA modulation extends its utility in repairing ischemia-induced cardiac damage. Exosomes harvested from diverse cell sources such as MSCs, macrophages, and adipose tissue have emerged as dynamic delivery vehicles, transferring cardioprotective miRNAs to damaged heart tissues. For instance, miR-132-3p-enriched exosomes from M2 macrophages accelerate post-infarction angiogenesis by targeting thrombospondin-1, a known angiogenesis inhibitor, thereby fostering vascular repair.

Further refinements include the pretreatment of MSC-derived exosomes with vericiguat, which augments the expression of miR-1180-3p targeting ETS1, consequently inhibiting fibroblast proliferation and curbing maladaptive cardiac fibrosis. Precision delivery mechanisms such as ultrasound-targeted microbubble disruption of miR-125b combined with MSC membrane ligands have demonstrated efficacy in reducing cardiomyocyte death and fibroblast growth, highlighting the intersection of bioengineering and gene regulation.

Genome editing technologies have also converged with exosome biology to enable cardiac-specific modulation of detrimental miRNAs. Loading single-guide RNA ribonucleoprotein complexes against miR-34a into cardiac-targeted EVs attenuates cardiomyocyte apoptosis, offering a powerful gene-editing paradigm for myocardial injury. Additionally, exosomal delivery of miRNA combinations like miR-148a-3p can reprogram cardiac fibroblasts into functional muscle cells, offering prospects not merely to limit damage but to regenerate myocardial tissue.

Cerebral infarction, often complicated by the impermeability of the blood-brain barrier, presents additional therapeutic challenges. Nevertheless, engineered extracellular vesicles embedded with superparamagnetic iron oxide nanoparticles display remarkable capability in traversing this barrier and restoring neuronal mitochondrial function through modulation of the miR-1228-5p/TRAF6/NOX1 axis. Similarly, miR-21-5p from adipose tissue-derived stem cell exosomes induces microglial polarization toward the anti-inflammatory M2 phenotype via the PIK3R1/PI3K/AKT pathway, mitigating post-stroke neuroinflammation.

Hypoxia-conditioned MSC exosomes enriched with miR-214-3p promote cerebral angiogenesis through the PTEN/Akt signaling pathway, highlighting the adaptability of stem cell derivatives in ischemic brain repair. Innovative probes exploiting aggregation-induced emission properties have been developed to label endothelial cell-derived EVs, which ferry miR-155-5p into astrocytes and stimulate neurological recovery by downregulating the pro-inflammatory c-Fos/AP-1 signaling axis.

Neuromodulatory strategies also include pre-treating astrocytes with berberine to induce extracellular vesicle release containing miR-182-5p, which targets Rac1 to suppress neuroinflammation, thereby improving brain injury outcomes. Nanodelivery platforms like the Ca-MOF system facilitate efficient miR-124 transport, promoting neural stem cell differentiation into mature neurons vital for functional restoration post-infarction.

Circular RNA (circRNA)-modified adipose-derived stem cell exosomes offer another layer of regulation by downregulating miR-124-3p in the hippocampus and upregulating SIRT7, effectively alleviating neuronal injury and converting microglia to an anti-inflammatory state. Such multilayered regulatory circuits reveal how epigenetic and post-transcriptional modifications can be harnessed synergistically for neuroprotection.

Complementing these biological strategies, certain chemical agents and physical therapies like electroacupuncture have demonstrated neuroprotective efficacy via miRNA modulation. Electroacupuncture upregulates miR-142-5p, suppressing ADAMTS1, and consequently activating the VEGF/PI3K/AKT/eNOS pathway, which reduces infarct size. Simultaneously, it modulates miR-7 expression to derepress KLF4/VEGF and angiopoietin-2, enhancing post-stroke angiogenesis. Acupuncture also elevates miR-34c-5p to enhance cellular autophagy, a critical survival pathway during ischemic stress.

Interventions at the extracellular vesicle level extend to lithium-pretreated MSCs, whose EVs carrying miR-1906 inhibit the NF-κB pathway by targeting TLR4, lowering inflammatory responses. Transcranial focused ultrasound stimulation has been shown to elevate Nespas expression, reducing miR-383-3p and permitting expression of SHP2, a regulator that mitigates microglial pro-inflammatory cytokine production, revealing non-pharmacological approaches to influence miRNA networks.

The translational promise of miRNA therapeutics lies in their dual capacity to target upstream pro-thrombotic and inflammatory mechanisms in both myocardial and cerebral infarctions, addressing the root causes of ischemic events. By developing antagonists or mimics against key miRNAs involved in thrombosis and vascular dysfunction, it is conceivable to achieve simultaneous protection against both heart attacks and strokes.

However, post-infarction phases demand broad-spectrum neuroprotective and cardioprotective miRNA strategies that attenuate reperfusion injury, modulate oxidative stress, and promote tissue remodeling. The dissimilar microenvironment, cellular architecture, and presence of the blood-brain barrier necessitate specialized delivery systems and targeted validation in each organ to avert off-target effects.

Notably, cerebral infarction therapies confront additional pharmacokinetic challenges due to the blood-brain barrier’s selective permeability. Innovative nanocarriers, engineered EVs, and peptide-modified delivery platforms are crucial to overcoming this hurdle, ensuring therapeutic miRNAs reach neuronal targets efficiently.

As research progresses, the convergence of molecular biology, nanotechnology, and bioengineering is poised to revolutionize treatment paradigms for cardiovascular and cerebrovascular diseases. Therapeutics that harness the intricate regulatory roles of miRNAs promise a future where heart and brain infarctions are not only better managed but potentially reversed at the molecular level.

This burgeoning field holds the key to unlocking precision medicine solutions that address the multifaceted nature of ischemic diseases, coupling targeted gene regulation with advanced delivery technologies. In doing so, miRNA-based therapies stand to transform the landscape of chronic vascular diseases and their acute catastrophic sequelae.

Subject of Research: Harnessing microRNA therapeutics in the treatment of heart and brain infarctions related to atherosclerosis.

Article Title: Harnessing miRNA therapeutics: a novel approach to combat heart and brain infarctions in atherosclerosis.

Article References:
Wang, J., Li, Y., Wang, H. et al. Harnessing miRNA therapeutics: a novel approach to combat heart and brain infarctions in atherosclerosis. Cell Death Discov. 11, 482 (2025). https://doi.org/10.1038/s41420-025-02649-9

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-025-02649-9